133 related articles for article (PubMed ID: 9775178)
1. [Tyrosine kinase: implications in tumor pathology and therapeutic perspectives].
Peyrade F; Taillan B; Lebrun C; Baron V; Dujardin P
Rev Med Interne; 1998 May; 19(5):366-72. PubMed ID: 9775178
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine kinases as targets in cancer therapy - successes and failures.
Traxler P
Expert Opin Ther Targets; 2003 Apr; 7(2):215-34. PubMed ID: 12667099
[TBL] [Abstract][Full Text] [Related]
3. Protein tyrosine kinases and cancer.
Kolibaba KS; Druker BJ
Biochim Biophys Acta; 1997 Dec; 1333(3):F217-48. PubMed ID: 9426205
[No Abstract] [Full Text] [Related]
4. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
[TBL] [Abstract][Full Text] [Related]
6. EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5.
Modjtahedi H; Affleck K; Stubberfield C; Dean C
Int J Oncol; 1998 Aug; 13(2):335-42. PubMed ID: 9664130
[TBL] [Abstract][Full Text] [Related]
7. Rational therapeutic intervention in cancer: kinases as drug targets.
Sawyers CL
Curr Opin Genet Dev; 2002 Feb; 12(1):111-5. PubMed ID: 11790564
[TBL] [Abstract][Full Text] [Related]
8. ErbB-targeted therapeutic approaches in human cancer.
Arteaga CL
Exp Cell Res; 2003 Mar; 284(1):122-30. PubMed ID: 12648471
[TBL] [Abstract][Full Text] [Related]
9. Activation of tyrosine kinases in cancer.
Vlahovic G; Crawford J
Oncologist; 2003; 8(6):531-8. PubMed ID: 14657531
[TBL] [Abstract][Full Text] [Related]
10. [Selective inhibition of tyrosine kinases - a new therapeutic principle in oncology].
Hochhaus A; Lahaye T; Kreil S; Berger U; Metzgeroth G; Hehlmann R
Onkologie; 2001 Sep; 24 Suppl 5():65-71. PubMed ID: 11600816
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor pathway inhibitors.
Baselga J; Cortes J
Cancer Chemother Biol Response Modif; 2005; 22():205-23. PubMed ID: 16110613
[No Abstract] [Full Text] [Related]
12. [Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia].
Buchdunger E
Med Klin (Munich); 2002 Jan; 97 Suppl 1():2-6. PubMed ID: 11831067
[TBL] [Abstract][Full Text] [Related]
13. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
Usui N
Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
[TBL] [Abstract][Full Text] [Related]
15. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.
Buchdunger E; Zimmermann J; Mett H; Meyer T; Müller M; Regenass U; Lydon NB
Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2558-62. PubMed ID: 7708684
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of epidermal growth factor receptor-associated tyrosine kinase blocks glioblastoma invasion of the brain.
Penar PL; Khoshyomn S; Bhushan A; Tritton TR
Neurosurgery; 1997 Jan; 40(1):141-51. PubMed ID: 8971836
[TBL] [Abstract][Full Text] [Related]
17. Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors.
Ramaraj P; Singh H; Niu N; Chu S; Holtz M; Yee JK; Bhatia R
Cancer Res; 2004 Aug; 64(15):5322-31. PubMed ID: 15289338
[TBL] [Abstract][Full Text] [Related]
18. Platelet-derived growth factor receptors: a therapeutic target in solid tumors.
George D
Semin Oncol; 2001 Oct; 28(5 Suppl 17):27-33. PubMed ID: 11740804
[TBL] [Abstract][Full Text] [Related]
19. [Anti-tyrosine kinase: the beginning of molecular therapies of cancer and initial results].
Guilhot F
Bull Cancer; 2001 Jul; 88(7):659-60. PubMed ID: 11495817
[No Abstract] [Full Text] [Related]
20. [The Philadelphia chromosome: from the gene to therapeutic methods].
Pérez-Losada J; González-Sarmiento R; Sánchez-García I
Sangre (Barc); 1998 Apr; 43(2):127-35. PubMed ID: 9656774
[No Abstract] [Full Text] [Related]
[Next] [New Search]
